在T-ALL/LBL中,PIM1是JAK/STAT路径突变调解的白血病原体效应的潜在治疗标
Antonio Lahera1,2,3, Laura Vela-Martín4,5,6, Pablo Fernández-Navarro7,8
1Department of Biology, Universidad Autónoma de Madrid, Madrid, 28049, Spain. a.lahera@cbm.csic.es.
NPJ precision oncology
|July 20, 2024
概括
前体T细胞急性淋巴细胞白血病/淋巴瘤 (T-ALL/LBL) 涉及JAK/STAT通路突变. 使用PIM447准PIM1过度表达,有望减少白血病发生和异常通路激活.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 前体T细胞瘤 (T-ALL/LBL) 是一种具有攻击性的血液性恶性瘤.
- 在T-ALL/LBL中,JAK/STAT通路经常发生变化,但缺乏向疗法.
- 确定新的治疗点对于这种患者群体至关重要.
研究的目的:
- 研究与T-ALL/LBL.中JAK/STAT通路突变相关的转录特征.
- 通过分析分子数据和细胞模型来确定潜在的治疗点.
- 评估针对T-ALL/LBL与JAK/STAT突变的PIM1的有效性.
主要方法:
- 从T-ALL/LBL患者的分子数据分析.
- 血造细胞模型的生成.
- 对PIM1基因表达的评估.
- 对泛PIM抑制剂PIM447疗效的评估.
主要成果:
- JAK/STAT路径突变与T-ALL/LBL中的异常转录特征相关.
- JAK/STAT突变导致PIM1基因过度表达.
- PIM447治疗减少了白血病发生和异常的c-MYC和mTOR通路激活.
结论:
- 在T-ALL/LBL中,PIM1是JAK/STAT路径突变的关键下游目标.
- PIM447对具有JAK/STAT突变的T-ALL/LBL患者的一个子集显示出治疗潜力.
- 向PIM1为T-ALL/LBL提供了一个新的治疗策略.
相关概念视频
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K


